Ellen Gould Chadwick
Affiliation: Children's Memorial Hospital
- Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of ageEllen Gould Chadwick
Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
Pediatr Infect Dis J 24:793-800. 2005..Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age...
- Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week resultsEllen G Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA
AIDS 22:249-55. 2008..To investigate pharmacokinetics, safety and efficacy of lopinavir/ritonavir (LPV/r)-based therapy in HIV-1-infected infants 6 weeks to 6 months of age...
- Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacyEllen Gould Chadwick
Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
Pediatr Infect Dis J 28:215-9. 2009....
- Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United StatesDeborah Persaud
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
J Infect Dis 195:1402-10. 2007....
- The PHACS SMARTT Study: Assessment of the Safety of In Utero Exposure to Antiretroviral DrugsRussell B Van Dyke
Department of Pediatrics, Tulane University School of Medicine, New Orleans, LA, USA
Front Immunol 7:199. 2016..However, several findings of concern warrant further evaluation, and new ARVs used in pregnancy need to be evaluated. ..
- Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected childrenRam Yogev
Division of Infectious Diseases, Children s Memorial Hospital, 2300 Children s Plaza, Box 155, Chicago, IL 60614, USA
Antimicrob Agents Chemother 49:336-41. 2005..Considerable interpatient variability was seen for all pharmacokinetic parameters of amprenavir. The results of this study suggest that 20 mg of amprenavir/kg administered twice a day should be used in future pediatric studies...
- Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitorsBrian L Robbins
St Jude Children s Research Hospital, Memphis, Tennessee, USA
Antimicrob Agents Chemother 52:3276-83. 2008....
- Mycobacterium gordonae bacteremia in an asymptomatic adolescent with acquired immunodeficiency syndromeRobert Garofalo
Division of Infectious Diseases, Children s Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 22:569-70. 2003..Illness related to M. gordonae infection ranges from localized infections to rare cases of disseminated disease. This report describes treatment of the first case of occult M. gordonae bacteremia in an adolescent with AIDS...
- Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazoleJudith A Guzman-Cottrill
Division of Infectious Disease, Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Children s Memorial Hospital, Chicago, IL, USA
Pediatr Infect Dis J 23:1059-61. 2004..Fusarium endocarditis is a rare and usually fatal disease. We report an immunocompromised child who survived Fusarium solani endocarditis despite the in vitro resistance of the organism to all available antifungal agents...